Amir Shojaei, Shire PLC (E);
Mahshad Darvish-Zargar, Abbott Medical Optics (C), Allergan (C), Novartis (C);
Edward Holland, Alcon Laboratories, Inc (C), Alcon Laboratories, Inc (R), Alcon Laboratories Inc. (F), Allergan (F), Allergan (C), Allergan (R), Bausch & Lomb (C), Bausch & Lomb (R), Kala Pharmaceuticals (C), Mati Therapeutics (F), Mati Therapeutics (C), Omeros (F), Omeros (C), Omeros (R), PRN (F), PRN (C), RPS (C), Senju Pharaceuticals (F), Senju Pharaceuticals (C), Senju Pharaceuticals (R), Shire/SARcode (C), Shire/SARcode (R), TearLab (C), TearScience (R), TearScience (C);
Clara Chan, Alcon Labs Inc. (C), Allergan (F), Allergan (C), Bausch & Lomb (C), Bausch and Lomb (F), TearLab (F), TearScience (C);
Kelly Nichols, Allergan (C), Eleven Biotherapeutics (F), InSite Vision Inc. (C), Kala Pharmaceuticals (F), Kala Pharmaceuticals (C), Parion Sciences (C), Santen (C), ScienceBased Health (C), Shire PLC (F), Shire PLC/SARcode (C), TearScience (F), Vistakon (F);
Joseph Tauber, Allergan (F), Bausch & Lomb (F), Senju Pharaceuticals (F), Shire/SARcode (R), Shire PLC (F);
Christophe BAUDOUIN, Alcon Laboratories, Inc (C), Allergan (C), Dompé (C), Horus Pharma (C), Santen Inc. (C), Thea Pharmaceuticals (C);
Aparna Raychaudhuri, Shire PLC (at the time of the study) (E);
monica roy, Shire PLC (E)